Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment (Core HTA 2)
The Core HTA is available online at the Core Model Online Tool here. Relevant document can be found as a pdf below. The aim of this core HTA was to compare Immunoglobulins (IGG) to placebo, not doing anything or Usual supportive
Presentations from the 3rd face to face training course for EUnetHTA Stakeholders organised by JA2WP2; April 23rd, Brussels. Brief introduction to EUnetHTA and its Tools, Marianne Klemp, NOKC The HTA Core Model® A brief introduction, Anna Nachtnebel, LBI-HTA How to
The 5th pilot rapid assessment of WP5 JA2 Strand B on “Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation” is now available.
The purpose of the assessment is to address the research question whether the use of the technologies in question is more effective and/or safer than their comparators, which were chosen based on CE mark indications, recommendations in clinical guidelines for
The aim of this core HTA was to compare Structured telephone support (STS) for adult patients with chronic heart failure compared to Usual care defined as regular schedules of visits of the patient at the heart center/ GP/cardiologist or patient
Publication of a JA2 methodological guideline – Internal validity of non-randomised studies (NRS) on interventions
During Joint Action 1 a methodological guideline on internal validity of randomised studies (RCT) had been elaborated. It was recommended from different sides that EUnetHTA should also produce and consent a guidance document for the assessment of non-randomised studies.
Levels of Evidence – Applicability of evidence for the context of a relative effectiveness assessment Amended JA1 Guideline Final Nov 2015
Levels of Evidence - Applicability of evidence for the context of a relative effectiveness assessment_Amended JA1 Guideline_Final Nov 2015
Joint “Rapid relative effectiveness assessment of new pharmaceuticals for the treatment of chronic Hepatitis C”
The purpose of the assessment is to evaluate multiple new pharmaceuticals for the treatment of Chronic Hepatitis C. Final version of the assessment was published in December 2015 Below is the documentation provided by the Joint Assessment authoring team: WP5-SA6 Final Appendix Feedback
Internal validity of non-randomised studies (NRS) on interventions_Guideline_Final Jul 2015
Please find below the summary of the EUnetHTA / EMA face-to-face meeting, 8 May 2015, in London, UK.2015-05-08 EMA-EUnetHTA - Meeting minutes - Final